AstraZeneca Oncology iScience Retains The Chase Group for Chief Scientific Leadership Position

AstraZeneca Oncology iScience Retains The Chase Group for Chief Scientific Leadership Position

The Chase Group has been retained to conduct a search to identify an industry leader to serve as the Chief Scientific Leader for their iSciences immune-oncology small molecule early development team. The Chief Scientist will be responsible for leading the strategy for AstraZeneca’s immune-oncology development efforts, along with being the interface with the biologics immune-oncology efforts at MedImmune. For more information, please contact chase@chasegroup.com.